Tarsus acquires iRenix Medical for up to $565 million to add late-stage eye drug IRX-101

On July 6, 2026, Tarsus Pharmaceuticals entered into a merger agreement to acquire iRenix Medical, a privately held ophthalmic biopharmaceutical company, with the deal completed and announced on July 8, 2026. A Tarsus merger subsidiary merged with and into iRenix, leaving iRenix as a wholly-owned subsidiary of the company.¹

The acquired asset, IRX-101, is described as an investigational ocular antiseptic based on a stable aqueous chlorine dioxide solution being developed to reduce post-procedural pain and corneal toxicity in patients receiving intravitreal therapy.¹ In the completed Phase 2b/3 RELIEF trial, which included 154 patients, IRX-101 showed statistically significant improvements on two co-primary endpoints compared with povidone-iodine: about a 50% relative reduction in post-procedural pain scores (p=0.0003), with half of the IRX-101 patients reporting a pain score of zero, and roughly a 25% relative reduction in corneal fluorescein staining (p=0.0003).¹

Tarsus said it plans to move forward with a Phase 3 study evaluating the tolerability and safety of IRX-101 versus povidone-iodine, aligned with FDA feedback, expected to begin enrolling in the first half of 2027 with results anticipated in 2028.¹

Financially, the upfront consideration consisted of $37,500,000 in cash, subject to customary adjustments, plus 607,093 shares of Tarsus common stock.¹ Beyond that, iRenix equityholders are eligible for milestone payments up to $490,000,000 tied to regulatory approval and commercial sales targets, along with revenue sharing in the low-to-mid single digits on future net sales of certain products.¹

On advisors, Piper Sandler & Co. served as exclusive financial advisor to iRenix, while DLA Piper LLP acted as legal counsel to iRenix.¹ Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP served as legal counsel to Tarsus in the transaction.¹